What is NED Biosystems?
NED Biosystems is dedicated to pioneering novel therapeutic solutions, with a primary focus on its patented NED-170 therapy for cancer. The company distinguishes itself through a comprehensive systems-based approach designed to maximize efficacy while minimizing patient toxicity. Beyond oncology, NED Biosystems is also advancing NED-260, a universal antiviral treatment aimed at combating a broad spectrum of infectious diseases. This dual-pronged strategy highlights the company's ambition to make a significant impact across multiple therapeutic areas.
How much funding has NED Biosystems raised?
NED Biosystems has raised a total of $2.1M across 2 funding rounds:
Series B
$2M
Debt
$64K
Series B (2018): $2M, investors not publicly disclosed
Debt (2021): $64K led by PPP
Key Investors in NED Biosystems
PPP
Public-Private Partnership
What's next for NED Biosystems?
The recent infusion of substantial expansion capital positions NED Biosystems for accelerated growth and the advancement of its clinical pipeline. This strategic financing is expected to fuel further research and development, potentially enabling the company to move its promising cancer and antiviral therapies closer to market. As a Public Benefit Corporation, NED Biosystems' trajectory is not only defined by commercial success but also by its mission to ensure broad patient access to life-changing treatments.
See full NED Biosystems company page
